menu
    • menu
    [{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"Muscarinic M2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Aroxybutynin","moa":"Muscarinic M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Aroxybutynin","moa":"Muscarinic M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Morningside Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Morningside Ventures"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"Atomoxetin Hydrochloride","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Alpha Wave Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aroxybutynin","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Apnimed \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Atomoxetin Hydrochloride

    Menu

    Atomoxetin Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apnimed Completes Enrollment in Phase 3 Study of AD109 for Obstructive Sleep Apnea

                            Details : AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic. It is being evaluated in phase 3 clinial trials for treating obstructive sleep apnea.

                            Brand Name : AD109

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 19, 2024

                            Lead Product(s) : Oxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apnimed Completes Enrollment in Phase 3 LunAIRo Study Of AD109

                            Details : AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic, aroxybutynin, with a selective NRI, atomoxetine. It is being evaluated for the treatment of obstructive sleep apnea.

                            Brand Name : AD109

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 09, 2024

                            Lead Product(s) : Oxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aroxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nig...

                            Details : AD109 (aroxybutynin + atomoxetine) combines a novel NCE selective antimuscarinic, aroxybutynin, with a selective norepinephrine reuptake inhibitor (NRI), atomoxetine. It is being evaluated in phase 3 clinial trials for the treatment of Obstructive Sleep ...

                            Brand Name : AD109

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 21, 2023

                            Lead Product(s) : Aroxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Night...

                            Details : AD109 (atomoxetine) has the potential to be the first nighttime oral pharmacologic treatment for people with OSA who are either intolerant of or refuse to use positive airway pressure (PAP) therapy.

                            Brand Name : AD109

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2023

                            Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Alpha Wave Ventures

                            Deal Size : $79.7 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trial...

                            Details : AD109 (atomoxetine) has the potential to be the first oral pharmacologic that both treats the underlying cause of OSA, airway obstruction at night, and improves daytime consequences of OSA such as fatigue.

                            Brand Name : AD109

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Alpha Wave Ventures

                            Deal Size : $79.7 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination fo...

                            Details : AD109 (atomoxetine) is first oral pharmacologic that treats OSA airway obstruction at night. It is a first-in-class, novel, investigational combination dosed once daily at bedtime and is designed to treat OSA patients across a broad spectrum of disease s...

                            Brand Name : AD109

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 28, 2022

                            Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data Show Clinically Meaningful Improvements for Investigational Oral Pharmacologic Treatment AD504 in Peo...

                            Details : AD504 (Atomoxetine) showed a significant reduction of the Apnea Hypopnea Index (AHI) (from 18.2 [11.8 to 31.3] on placebo to 7.4 [5.4 to 16.1] events/h on AD504, p=0.024 and Hypoxic Burden (HB) from 46.3 [25.1 to 88.3] on placebo to 18.7 [14.9 to 43.5], ...

                            Brand Name : AD504

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 02, 2022

                            Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022

                            Details : Positive data on investigational oral pharmacologic treatment AD109 showed statistically significant and clinically meaningful benefits for patients with obstructive sleep apnea.

                            Brand Name : AD109

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : Atomoxetin Hydrochloride,Aroxybutynin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study With Oral Therapeutic Candidates AD504...

                            Details : AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in apnea hypopnea index (AHI) from placebo, which was the study’s primary endpoint.

                            Brand Name : AD504

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 16, 2021

                            Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aroxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Morningside Ventures

                            Deal Size : $25.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Apnimed Closes Series B Financing to Advance Once-Daily Oral Medication for Obstructive Sleep Apnea (OSA)

                            Details : The proceeds will support Apnimed’s ongoing development and commercialization plans. The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea, which is currently in late-stage ...

                            Brand Name : AD109

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 25, 2021

                            Lead Product(s) : Aroxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Morningside Ventures

                            Deal Size : $25.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth